RxDoctor Payments Data

Davinder Dhingra, MD

Psychiatry · Fort Worth, TXNPI 1912065517

Payments from drug & device makers

$5,374in general payments, 2019–2025

Across 155 payments — averaging $34.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$782
  • Johnson & Johnson$735
  • E.r. Squibb & Sons, L.L.C.$576
  • Otsuka America Pharmaceutical, Inc.$552
  • AbbVie$529
  • plus $1K from 9 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$5,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,374 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$7,326
Medicare patients
22
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate58$192,090
AustedoDeutetrabenazine17$125,374
IngrezzaValbenazine Tosylate14$107,398
VraylarCariprazine Hcl32$53,843
Abilify MaintenaAripiprazole14$37,026
LybalviOlanzapine/Samidorphan Malate12$22,041
Aripiprazole79$4,849
Clozapine27$3,818
Lurasidone Hcl34$2,309
Paliperidone ErPaliperidone12$1,829
Hydroxyzine Pamoate133$1,805
Olanzapine107$1,794
Oxcarbazepine54$1,665
Divalproex Sodium ErDivalproex Sodium38$1,454
Ziprasidone Hcl37$1,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$735$192,09058 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,145$125,37417 claims
Neurocrine Biosciences, Inc.Ingrezza$782$107,39814 claims
AbbVieVraylar$529$53,84332 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$552$37,02614 claims
Alkermes, Inc.Lybalvi$124$22,04112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →